Northern Trust’s Moleculin Biotech MBRX Stock Holding History

Northern Trust’s Portfolio MBRX Stock Details MBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-7	Closed	-$46K	–	4455
2023 Q4	$46K	Hold	7	–	–	﹤0.01%	4248
2023 Q3	$22.9K	Hold	7	–	–	﹤0.01%	4309
2023 Q2	$31K	Hold	7	–	–	﹤0.01%	4323
2023 Q1	$51.5K	Buy	7 +1	+17%	+$8.76K	﹤0.01%	4263
2022 Q4	$49.1K	Hold	6	–	–	﹤0.01%	4290
2022 Q3	$49K	Hold	6	–	–	﹤0.01%	4327
2022 Q2	$67K	Sell	6 -1	-14%	-$11.6K	﹤0.01%	4319
2022 Q1	$90K	Hold	7	–	–	﹤0.01%	4382
2021 Q4	$94K	Hold	7	–	–	﹤0.01%	4440
2021 Q3	$152K	Hold	7	–	–	﹤0.01%	4273
2021 Q2	$186K	Hold	7	–	–	﹤0.01%	4183
2021 Q1	$207K	Buy	7 +5	+250%	+$183K	﹤0.01%	4108
2020 Q4	$71K	Hold	2	–	–	﹤0.01%	4182
2020 Q3	$72K	Hold	2	–	–	﹤0.01%	4038
2020 Q2	$82K	Buy	2 +1	+100%	+$47.4K	﹤0.01%	3962
2020 Q1	$40K	Hold	1	–	–	﹤0.01%	3987
2019 Q4	$61K	Hold	1	–	–	﹤0.01%	4022
2019 Q3	$74K	Hold	1	–	–	﹤0.01%	3986
2019 Q2	$60K	Hold	1	–	–	﹤0.01%	4054
2019 Q1	$39K	Hold	1	–	–	﹤0.01%	4063
2018 Q4	$50K	Hold	1	–	–	﹤0.01%	4051
2018 Q3	$37K	Hold	1	–	–	﹤0.01%	4166
2018 Q2	$41K	Buy	+1	New	+$81.9K	﹤0.01%	4143
2018 Q1	–	Hold	0	–	–	–	4153
2017 Q4	–	Hold	0	–	–	–	4137
2017 Q3	–	Hold	0	–	–	–	4127
2017 Q2	–	Hold	0	–	–	–	4178
2017 Q1	–	Hold	0	–	–	–	4184

Other funds holding MBRX

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Atticus Wealth Management Palm Beach Gardens, Florida $452M AUM 17.19% 1-Year Est. Return

Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

FIM

FWL Investment Management Dallas, Texas $545M AUM 64.06% 1-Year Est. Return

NBC Securities Birmingham, Alabama $1.47B AUM 20.38% 1-Year Est. Return

Northern Trust's MBRX Position: Q1 2024 in Review

Northern Trust sold out of Moleculin Biotech (MBRX) in Q1 2024, closing a stake of 7 shares — an estimated $46K sold.

Northern Trust first reported a position in MBRX in Q2 2018 and held it in 23 quarters. The position peaked at $207K in Q1 2021. 9 funds tracked by Wall St. Rank hold MBRX as of Q1 2024.

Northern Trust reported no remaining Moleculin Biotech position as of Q1 2024 after selling out during the quarter.
Northern Trust sold 7 Moleculin Biotech shares in Q1 2024, an estimated $46K.
Northern Trust first reported a position in Moleculin Biotech in Q2 2018 and held it in 23 quarters.
Northern Trust's Moleculin Biotech position peaked at $207K in Q1 2021.
9 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2024.

Based on Northern Trust's 13F filing for Q1 2024, filed 14 May 2024.